Thursday Nov 07, 2024
FT
Thursday Nov 07, 2024
Tuesday, 28 November 2017 00:00 - - {{hitsCtrl.values.hits}}
The Apollo Hospitals Group, India’s largest integrated healthcare provider announced the launch of a portfolio of cutting edge diagnostics services for infectious diseases. The new line of tests is being offered in partnership with Credence Genomics, and is based on a specialised DNA diagnostics platform offering faster and more precise diagnosis. 
Through this partnership, Credence Genomics’ flagship products – the Rapid Infection Detection (RID), Bactfast and Fungifast will now be readily available to benefit patients and assist the medical fraternity in India by offering fast and precise diagnosis for infectious diseases. While announcing the launch, Apollo Hospitals Group Vice Chairperson Dr. Preetha Reddy said, “It has been our constant endeavour to ensure the most superior technology-based clinical solutions are made available to our patients. Through the introduction of this service portfolio, patients will benefit immensely through faster and more accurate diagnosis for infectious diseases. Bacterial and fungal infectious diseases take a great toll on populations of the sub-continent. The need for effective and timely diagnosis can significantly lower morbidity and mortality associated with this disease cohort. Through this partnership we are hopeful of offering a meaningful change to the diagnostics landscape in our country.”
The diagnostic products Credence RID, Bactfast and Fungifast are diagnostic tests which can diagnose any infectious disease caused by a bacteria or fungi with over 90% accuracy. The scope, methodology and accuracy of results are further corroborated by a recent BioMed Central (BMC) Infectious Diseases publication. These tests, now proven for their speed and accuracy in the reporting of results, have established the trust of the medical community in the domestic market in both public and private sector hospitals.
Credence Genomics Founding CEO and Director Dr. Vaz Gnanam further added, “We join hands with the Apollo Group in delivering the highest standards in healthcare in total alignment to their global credibility and brand promise. We are very excited to explore pioneering endeavours on which both companies could come together, to benefit society beyond the boundaries of countries and territories in the realm of medical science and its progress.”
Credence Genomics is a Sri Lankan establishment pioneering in the development of leading-edge innovations on specialised DNA diagnostics based on the next generation sequencing platform with intensive research infrastructure and capabilities. As part of the collaborations Credence Genomics will set up a state-of-the-art DNA research/diagnostics facility in Chennai. The facility will be managed by a team of leading scientists from all across India and will be fully operational by mid-December.
